| Methods |
Adequate allocation generation, open, no ITT, no drop‐outs |
| Participants |
Household contacts, USA |
| Interventions |
Rifampin: > 66 lb weight 4 x 600 mg/day; < 66 lb 4 x 300 mg/day versus none |
| Outcomes |
Morbidity, eradication, failure serogroup
Follow‐up: 130 days |
| Notes |
Data presented for carriers. Main serogroups: C, N |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Low risk |
Adequate allocation generation |
| Allocation concealment (selection bias) |
Unclear risk |
Unclear |
| Blinding of participants and personnel (performance bias)
All outcomes |
High risk |
Open |
| Blinding of outcome assessment (detection bias)
All outcomes |
High risk |
Open |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
No drop‐outs |
| Selective reporting (reporting bias) |
Low risk |
No evidence |
| Other bias |
Low risk |
No evidence |
